• Doximity, Inc. recently reported its fiscal 2027 first‑quarter results, with revenue of US$156.62 million versus US$145.91 million a year earlier, but net income fell to US$24.32 million from US$53.32 million, and the company issued updated guidance calling for second‑quarter revenue of US$170 million–US$171 million and full‑year revenue of US$671 million–US$681 million.
• Management also highlighted growing use of its AI‑powered tools across the clinician network, pointing to deeper engagement that could support its long‑term healthcare platform ambitions.
• Now we’ll explore how Doximity’s revenue beat and higher full‑year guidance may influence the existing investment narrative around its AI‑driven platform.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Doximity Investment Narrative Recap

To own Doximity, you need to believe its clinician network and AI tools can deepen workflow adoption enough to offset margin pressure and a heavy reliance on pharma marketing budgets. The latest quarter’s revenue beat and slightly higher full year guidance support the near term catalyst around sustained top line growth, but the sharp drop in net income keeps the key risk of profitability pressure and slower AI monetization very much in focus rather than materially changing it.

The most relevant recent announcement is Doximity’s updated fiscal 2027 outlook, now calling for US$671 million to US$681 million in revenue after delivering US$156.62 million this quarter. This tighter, higher range reinforces the catalyst that growing AI powered engagement could support steadier revenue, even as investors weigh whether weaker earnings, higher operating costs and policy uncertainty around pharma marketing might constrain how much value the platform can ultimately capture.

Yet behind this improving guidance, investors should be aware of the growing tension between AI investment, rising costs and potential regulatory shifts that could...

Doximity’s narrative projects $766.5 million revenue and $212.2 million earnings by 2029.

Uncover how Doximity's forecasts yield a $24.37 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranking analysts were already expecting revenue of about US$733.8 million and earnings of roughly US$166.9 million by 2029, and they worry that rising compliance costs and data privacy rules could restrict Doximity’s high margin ad products. After this quarter’s revenue beat but lower net income, their more pessimistic view may or may not gain traction, which is why it is worth comparing how differently you and these analysts weigh AI growth against margin pressure.

Explore 5 other fair value estimates on Doximity - why the stock might be worth as much as 79% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Doximity research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.